Having proved that bombesin-based Dau conjugates are helpful tools to target cancer cells, our next aim is to generate novel cathepsin-labile conjugates with the homing peptides of L5 and L6, and a more potent toxic payload, such as auristatins, to achieve a stronger efficacy while maintaining their selectivity. The gene discussed is GRP; the disease is cancer.